표적 항암 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global targeted cancer therapy market size is expected to reach USD 180.47 Billion in 2034 from USD 98.58 Billion in 2025, growing at a CAGR of 6.95 during 2026-2034.This market is experiencing rapid growth due to increasing adoption of precision medicine approaches in oncology treatment. Targeted cancer therapies are designed to attack specific molecular pathways and genetic abnormalities associated with cancer progression, offering improved treatment effectiveness and reduced side effects compared to conventional therapies. Rising cancer prevalence, advances in genomic research, and growing awareness of personalized treatment options are supporting market expansion. Healthcare providers are increasingly utilizing targeted therapies to improve patient outcomes.

The market is benefiting from continuous innovation in molecular diagnostics, biomarker identification, and drug development. Pharmaceutical companies are investing heavily in research programs aimed at developing therapies that address specific cancer mutations and signaling pathways. Expanding clinical trial activity and regulatory support for precision oncology are creating significant growth opportunities. Additionally, improvements in companion diagnostic technologies are enabling more accurate patient selection and treatment planning.

Future prospects remain exceptionally strong as advances in genomics and biotechnology continue transforming cancer care. Emerging therapies targeting novel molecular pathways and rare cancer types are expected to broaden treatment options. Increasing integration of artificial intelligence and genomic analytics will further enhance drug discovery and personalized treatment strategies. As healthcare systems emphasize precision medicine, the targeted cancer therapy market is projected to experience sustained long-term growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Therapy Type

• Small Molecule Drugs
• Monoclonal Antibodies
• Immunotherapies
• Others

By Cancer Type

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Blood Cancer
• Gynecologic Cancer
• Others

By End User

• Hospitals
• Cancer and Radiation Therapy Centers
• Specialty Clinics

COMPANIES PROFILED

• Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Eli Lilly and Company, Sanofi S.A.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL TARGETED CANCER THERAPY MARKET: BY THERAPY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapy Type
• 4.2. Small Molecule Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Immunotherapies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL TARGETED CANCER THERAPY MARKET: BY CANCER TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Cancer Type
• 5.2. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Blood Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Gynecologic Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL TARGETED CANCER THERAPY MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Cancer and Radiation Therapy Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL TARGETED CANCER THERAPY MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Therapy Type
  • 7.2.2 By Cancer Type
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Therapy Type
  • 7.3.2 By Cancer Type
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Therapy Type
  • 7.4.2 By Cancer Type
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Therapy Type
  • 7.5.2 By Cancer Type
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Therapy Type
  • 7.6.2 By Cancer Type
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL TARGETED CANCER THERAPY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Amgen Inc
  • 9.2.2 AstraZeneca Plc
  • 9.2.3 Bayer AG
  • 9.2.4 Bristol-Myers Squibb Company
  • 9.2.5 F. Hoffmann-La Roche Ltd
  • 9.2.6 GlaxoSmithKline Plc
  • 9.2.7 Johnson & Johnson
  • 9.2.8 Merck & Co.Inc
  • 9.2.9 Novartis AG
  • 9.2.10 Pfizer Inc
  • 9.2.11 Eli Lilly And Company
  • 9.2.12 Sanofi S.A